Az inzulinrezisztencia és a nyálmirigydaganatok epidemiológiai összefüggései

Translated title of the contribution: Epidemiological correlations of insulin resistance and salivary gland tumors

Z. Suba, J. Barabás, Dániel Takács, György Szabó, M. Ujpál

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: The metabolic syndrome develops on the basis of peripheral insulin resistance. It is a continuously progressing metabolic disorder, which concludes finally into serious diseases. Type-2 diabetes, cardiovascular disease and - according to the recent literature - malignancies are the most important consequences. A well-known fact, that metabolic disorders; such as diabetes and obesity, can deeply influence the structure and function of the salivary glands. Considering these data, the question arises; is there any correlation among insulinresistance, type-2 diabetes and salivary gland tumors? Aims: A retrospective epidemiological examination was performed to analyze the correlations between salivary gland tumors and insulin resistance states (type-2 diabetes and metabolic syndrome). Methods: Data of 438 patients were analyzed in the Maxillofacial Surgery Clinic of the Semmelweis University. In 224 cases salivary gland tumors were surgically removed. In 214 control cases, bone replacement, or artificial root implantation was the intervention. Known, treated and newly diagnosed diabetic cases were included in the DM group. Cases exhibiting at least 3 of the 5 criteria of the metabolic syndrome composed the MS group. The remaining cases were included in the nonDM-nonMS group. The frequencies of cardiovascular diseases and of primary tumors at other sites were registered in the different groups. Results: Type-2 diabetes was significantly more frequent in the tumorous group (22.8%) than in the controls (6.5%) (p <0.001). Similarly, the metabolic syndrome was much more frequent among the tumorous cases (31.3%) as compared with the control group (7.9%) (p <0.001). The rate of cardiovascular diseases was significantly higher in the DM and MS subgroups of the tumorous patients (15.6% and 17.1%, respectively) as compared with the controls (5.6%) (p <0.05 and p <0.01, respectively). The rate of primary tumors of other sites, as concerns both tumors overall and malignancies, was significantly higher among the salivary gland tumorous cases (17.8% and 8.9%, respectively) than among the controls (8.4% and 2.8%, respectively) (p <0.01 and p <0.05, respectively). In the DM and MS subgroups of the tumorous cases the rate of primary tumors was even higher (28.0% and 22.9%, respectively), however, that for the nonDM-nonMS subgroup was similar to that for controls (9.7). Conclusions: Considering the present results and the literature data a better control of insulinresistant states seems to be necessary, not only to reduce the cardiovascular risk, but also to prevent tumor promotion.

Original languageHungarian
Pages (from-to)1727-1732
Number of pages6
JournalOrvosi Hetilap
Volume146
Issue number33
Publication statusPublished - 2005

Fingerprint

Glandular and Epithelial Neoplasms
Insulin Resistance
Type 2 Diabetes Mellitus
Neoplasms
Cardiovascular Diseases
Salivary Glands
Oral Surgery
Vascular Resistance
Obesity
Bone and Bones
Control Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az inzulinrezisztencia és a nyálmirigydaganatok epidemiológiai összefüggései. / Suba, Z.; Barabás, J.; Takács, Dániel; Szabó, György; Ujpál, M.

In: Orvosi Hetilap, Vol. 146, No. 33, 2005, p. 1727-1732.

Research output: Contribution to journalArticle

@article{26840cc4f4f64db9832193caf4f6546a,
title = "Az inzulinrezisztencia {\'e}s a ny{\'a}lmirigydaganatok epidemiol{\'o}giai {\"o}sszef{\"u}gg{\'e}sei",
abstract = "Introduction: The metabolic syndrome develops on the basis of peripheral insulin resistance. It is a continuously progressing metabolic disorder, which concludes finally into serious diseases. Type-2 diabetes, cardiovascular disease and - according to the recent literature - malignancies are the most important consequences. A well-known fact, that metabolic disorders; such as diabetes and obesity, can deeply influence the structure and function of the salivary glands. Considering these data, the question arises; is there any correlation among insulinresistance, type-2 diabetes and salivary gland tumors? Aims: A retrospective epidemiological examination was performed to analyze the correlations between salivary gland tumors and insulin resistance states (type-2 diabetes and metabolic syndrome). Methods: Data of 438 patients were analyzed in the Maxillofacial Surgery Clinic of the Semmelweis University. In 224 cases salivary gland tumors were surgically removed. In 214 control cases, bone replacement, or artificial root implantation was the intervention. Known, treated and newly diagnosed diabetic cases were included in the DM group. Cases exhibiting at least 3 of the 5 criteria of the metabolic syndrome composed the MS group. The remaining cases were included in the nonDM-nonMS group. The frequencies of cardiovascular diseases and of primary tumors at other sites were registered in the different groups. Results: Type-2 diabetes was significantly more frequent in the tumorous group (22.8{\%}) than in the controls (6.5{\%}) (p <0.001). Similarly, the metabolic syndrome was much more frequent among the tumorous cases (31.3{\%}) as compared with the control group (7.9{\%}) (p <0.001). The rate of cardiovascular diseases was significantly higher in the DM and MS subgroups of the tumorous patients (15.6{\%} and 17.1{\%}, respectively) as compared with the controls (5.6{\%}) (p <0.05 and p <0.01, respectively). The rate of primary tumors of other sites, as concerns both tumors overall and malignancies, was significantly higher among the salivary gland tumorous cases (17.8{\%} and 8.9{\%}, respectively) than among the controls (8.4{\%} and 2.8{\%}, respectively) (p <0.01 and p <0.05, respectively). In the DM and MS subgroups of the tumorous cases the rate of primary tumors was even higher (28.0{\%} and 22.9{\%}, respectively), however, that for the nonDM-nonMS subgroup was similar to that for controls (9.7). Conclusions: Considering the present results and the literature data a better control of insulinresistant states seems to be necessary, not only to reduce the cardiovascular risk, but also to prevent tumor promotion.",
keywords = "Insulinresistence, Metabolic syndrome, Salivary gland tumor, Type-2 diabetes",
author = "Z. Suba and J. Barab{\'a}s and D{\'a}niel Tak{\'a}cs and Gy{\"o}rgy Szab{\'o} and M. Ujp{\'a}l",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "1727--1732",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "33",

}

TY - JOUR

T1 - Az inzulinrezisztencia és a nyálmirigydaganatok epidemiológiai összefüggései

AU - Suba, Z.

AU - Barabás, J.

AU - Takács, Dániel

AU - Szabó, György

AU - Ujpál, M.

PY - 2005

Y1 - 2005

N2 - Introduction: The metabolic syndrome develops on the basis of peripheral insulin resistance. It is a continuously progressing metabolic disorder, which concludes finally into serious diseases. Type-2 diabetes, cardiovascular disease and - according to the recent literature - malignancies are the most important consequences. A well-known fact, that metabolic disorders; such as diabetes and obesity, can deeply influence the structure and function of the salivary glands. Considering these data, the question arises; is there any correlation among insulinresistance, type-2 diabetes and salivary gland tumors? Aims: A retrospective epidemiological examination was performed to analyze the correlations between salivary gland tumors and insulin resistance states (type-2 diabetes and metabolic syndrome). Methods: Data of 438 patients were analyzed in the Maxillofacial Surgery Clinic of the Semmelweis University. In 224 cases salivary gland tumors were surgically removed. In 214 control cases, bone replacement, or artificial root implantation was the intervention. Known, treated and newly diagnosed diabetic cases were included in the DM group. Cases exhibiting at least 3 of the 5 criteria of the metabolic syndrome composed the MS group. The remaining cases were included in the nonDM-nonMS group. The frequencies of cardiovascular diseases and of primary tumors at other sites were registered in the different groups. Results: Type-2 diabetes was significantly more frequent in the tumorous group (22.8%) than in the controls (6.5%) (p <0.001). Similarly, the metabolic syndrome was much more frequent among the tumorous cases (31.3%) as compared with the control group (7.9%) (p <0.001). The rate of cardiovascular diseases was significantly higher in the DM and MS subgroups of the tumorous patients (15.6% and 17.1%, respectively) as compared with the controls (5.6%) (p <0.05 and p <0.01, respectively). The rate of primary tumors of other sites, as concerns both tumors overall and malignancies, was significantly higher among the salivary gland tumorous cases (17.8% and 8.9%, respectively) than among the controls (8.4% and 2.8%, respectively) (p <0.01 and p <0.05, respectively). In the DM and MS subgroups of the tumorous cases the rate of primary tumors was even higher (28.0% and 22.9%, respectively), however, that for the nonDM-nonMS subgroup was similar to that for controls (9.7). Conclusions: Considering the present results and the literature data a better control of insulinresistant states seems to be necessary, not only to reduce the cardiovascular risk, but also to prevent tumor promotion.

AB - Introduction: The metabolic syndrome develops on the basis of peripheral insulin resistance. It is a continuously progressing metabolic disorder, which concludes finally into serious diseases. Type-2 diabetes, cardiovascular disease and - according to the recent literature - malignancies are the most important consequences. A well-known fact, that metabolic disorders; such as diabetes and obesity, can deeply influence the structure and function of the salivary glands. Considering these data, the question arises; is there any correlation among insulinresistance, type-2 diabetes and salivary gland tumors? Aims: A retrospective epidemiological examination was performed to analyze the correlations between salivary gland tumors and insulin resistance states (type-2 diabetes and metabolic syndrome). Methods: Data of 438 patients were analyzed in the Maxillofacial Surgery Clinic of the Semmelweis University. In 224 cases salivary gland tumors were surgically removed. In 214 control cases, bone replacement, or artificial root implantation was the intervention. Known, treated and newly diagnosed diabetic cases were included in the DM group. Cases exhibiting at least 3 of the 5 criteria of the metabolic syndrome composed the MS group. The remaining cases were included in the nonDM-nonMS group. The frequencies of cardiovascular diseases and of primary tumors at other sites were registered in the different groups. Results: Type-2 diabetes was significantly more frequent in the tumorous group (22.8%) than in the controls (6.5%) (p <0.001). Similarly, the metabolic syndrome was much more frequent among the tumorous cases (31.3%) as compared with the control group (7.9%) (p <0.001). The rate of cardiovascular diseases was significantly higher in the DM and MS subgroups of the tumorous patients (15.6% and 17.1%, respectively) as compared with the controls (5.6%) (p <0.05 and p <0.01, respectively). The rate of primary tumors of other sites, as concerns both tumors overall and malignancies, was significantly higher among the salivary gland tumorous cases (17.8% and 8.9%, respectively) than among the controls (8.4% and 2.8%, respectively) (p <0.01 and p <0.05, respectively). In the DM and MS subgroups of the tumorous cases the rate of primary tumors was even higher (28.0% and 22.9%, respectively), however, that for the nonDM-nonMS subgroup was similar to that for controls (9.7). Conclusions: Considering the present results and the literature data a better control of insulinresistant states seems to be necessary, not only to reduce the cardiovascular risk, but also to prevent tumor promotion.

KW - Insulinresistence

KW - Metabolic syndrome

KW - Salivary gland tumor

KW - Type-2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=32944456385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944456385&partnerID=8YFLogxK

M3 - Article

C2 - 16206887

AN - SCOPUS:32944456385

VL - 146

SP - 1727

EP - 1732

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 33

ER -